Vyjuvek: how was the first human dose set?

The public FDA and EMA reviews of Vyjuvek don't say how the first human dose was chosen. That rationale is in the IND, which is confidential, so it is missing for most approved products.

FDA expects preclinical proof-of-concept and toxicology studies to identify active dose levels and support the choice of starting dose and escalation. The 2013 guidance gives no numeric formula or scaling rule for the starting dose.

NOAEL / key findings: NOAEL 6.9e6 pfu (low dose) in mouse intradermal study; dose-site scabbing, inflammatory lymphocyte hyperplasia; no adverse findings per FDA (EMA assessment report, p. 32)

Full method, every step sourced →